Abstract Nicotinic acetylcholine receptors (nAChRs) play a crucial role in a number of clinically relevant mental and neurological pathways, as well as autonomic and immune functions. The development of subtype-selective ligands for nAChRs therefore is potentially useful for targeted therapeutic management of conditions where nAChRs are involved. We tested if selectivity for a particular nAChR subtype can be achieved through small structural modifications of a lead compound containing the nicotinic pharmacophore by changing the distance between the electronegative elements. For this purpose, analogs of A-84543 were designed, synthesized and characterized as potentially new nAChR subtype-selective ligands. Compounds were tested for their binding properties in rat cerebral cortical tissue homogenates, and subtype-selectivity was determined using stably transfected HEK cells expressing different nAChR subtypes. All compounds synthesized were found to competitively displace [ 3 H]-epibatidine ([ 3 H]EB) from the nAChR binding site. Of all the analogues, H-11MNH showed highest affinity for nAChRs compared to a *fivefold to tenfold lower affinity of A-84543. All other compounds had affinities [10,000 nM. Both A-84543 and H-11MNH have highest affinity for a2b2 and a4b2 nAChRs and show moderate affinity for b4-and a7-containing receptors. H-11MNH was found to be a full agonist with high potency at a3b4, while A-84543 is a partial agonist with low potency. Based on their unique pharmacological binding properties we suggest that A-84543 and its desmethylpyrrolidine analog can be useful as pharmacological ligands for studying nAChRs if selective pharmacological and/or genetic tools are used to mask the function of other receptors subtypes.
Introduction
Over the past two decades a number of CNS disorders (Alzheimer's, Parkinson's, attention deficit hyperactivity disorder (ADHD), schizophrenia, addiction, among others) [1] [2] [3] [4] and some ANS dysfunctions (such as autonomic neuropathies and autoimmune autonomic ganglionopathy), as well as neuropathic pain and inflammatory conditions [5] [6] [7] [8] , have been found to have either a direct or indirect involvement of the neurotransmitter acetylcholine (ACh) Special Issue: In honor of Dr. Lynn Wecker.
and its nicotinic acetylcholine receptors (nAChRs). The nAChRs comprise a large group of ligand-gated ion channels with a hetero-or homo-pentamer configuration that have diverse subunit stoichiometries [9] . Electrophysiological data on in vitro systems expressing individual receptor subtypes, however, has clearly demonstrated that each nAChR subtype is physiologically and pharmacologically distinct in their response to stimulation by ACh, as well as by a variety of natural and synthetic compounds [2, 3, [10] [11] [12] . The diversity of the nicotinic acetylcholine receptors (nAChRs) in brain, ganglia and a large group of non-neuronal tissues [1, 2, 13] , presents important opportunities for the development of nAChR subtype-selective compounds to manage many different conditions. This realization has prompted a large number of studies to find selective drugs for each receptor subtype. Unfortunately, the nAChR subunits share a high (*90 %) degree of structural homology in their amino acid sequences [14, 15] including a conserved orthosteric binding site [16] , the ACh binding site. This close homology has hindered detailed characterization of their individual functional roles and has made it difficult to design nAChR subtype-specific ligands for use as therapeutic agents. One positive outcome of these studies has been the development of ligands for the a4b2 nAChR, the most abundant in the CNS [17] , and the one that has been the least challenging. In general, the b2-containing subtypes have received the most attention, partly because, with very few exceptions, old and new nicotinic ligands show highest affinity [18] [19] [20] [21] [22] [23] and/or higher selectivity for these receptors [2, [22] [23] [24] [25] [26] [27] [28] . It should be emphasized here, however, that selectivity of all nicotinic drugs so far studied is at best relative, and highly dependent on concentration [24, 25, 28] . Even at low concentrations some of these drugs are quite promiscuous and may bind all, or almost all, neuronal nAChRs. Nonetheless, one may still find these less than perfectly selective compounds useful in a variety of ways. One can, for example, use their selectivity ratios, that is, the ratio between their affinity for one receptor subtype vs another (i.e. affinity for a4b2/affinity of a3b4) [24, 25] or their pharmacological footprint (affinity profile, potency profile and efficacy profile) [28] . Understanding their limitations and relative selectivity is important to better ascertain their functionality, design experiments, and interpret the data.
One approach to understanding nAChRs subtypes has been to develop new compounds through the rational modification of well-known active nAChR lead compounds. According to a pre-existing pharmacophore model for nicotine, initially proposed in 1970 by Beers and Reich [29] and later modified by others [30] , compounds will fit the nAChRs orthosteric site if they meet certain criteria (see Fig. 1 for details). Thus, minor structural modifications on nicotine has yielded a number of useful ligands including A-85380 [23] , A-84543 [22] , sazetidine-A [34] and many of their analogues [22, 23, [31] [32] [33] , which, although not fully selective, have diverse affinities and high affinity ratios for different nAChR subtypes [22-28, 31-33, for review see 2, 9], unfortunately, most have not been as successful in the clinic [2, 4] .
Another lead compound, epibatidine, an alkaloid like nicotine, and its iodinated-analog ([ 125 I]-IPH) exhibit some of the highest affinities (pM-nM) at most nAChR subtypes [19, 20, [34] [35] [36] [37] , however, they lacks nAChR selectivity [19, 20, 36] . Analogues of epibatidine were also synthesized and some were found to have improved binding and functional selectivity for nAChR subtypes when the position of the nitrogen in the pyridine ring was moved to the ortho position [21] , but lost efficacy.
Although most drugs will distinguish somewhat between b2-containing vs b4-containing receptors and some have a high selectivity ratio between them, it is crucially important to be able to also differentiate between b2-containing or b4-containing receptor subtypes themselves, since they have very important and distinct functions. For example, with regards to the b2-containing nAChRs, a4b2 nAChRs are primarily cortical and are involved in learning, memory, and attention [1] [2] [3] , among other functions. In contrast, a6b2* 1 nAChRs are expressed at much lower and discrete levels in dopamine terminals and are involved primarily, but not exclusively, in dopamine release [38, 39] , and thus may be involved in and can affect addiction [40] , ADHD, Parkinson's disease, and schizophrenia [1] [2] [3] . Fig. 1 Model of the nicotinic receptor pharmacophore. The typical nicotinic structure at left, was modified as seen at right in compound H-11MNH. This new molecule fits the pharmacophore model. The pharmacophore usually consists of a protonated nitrogen and a hydrogen bond donor. The optimum N-N distance between the protonated nitrogen, which acts as a hydrogen bond donor, and the nonprotonated nitrogen which acts as the hydrogen bond acceptor, is estimated to be 5.5 Å based on measurements obtained from one of the highest affinity nicotinic compounds, epibatidine. For H-11MNH, N-N is 7.11 Å . For all analogs made here it varied between 6.4 and 8.2 Å . C, center of the electronegative element nAChRs containing a3 and b2 subunits, on the other hand, are found prominently in sympathetic nerve terminals [41] and can strongly affect vasodilation of cerebral arteries [41, 42] . Therefore, development of ligands that can discriminate between these three subset of receptors would be relevant for the management of subtype-specific nAChRlinked disorder, although non-b2-containing nAChRs may also be involved.
Using this rationale, A-84543, a 3-pyridyl ether analog of nicotine and with a high affinity for a4b2 receptors [22, 32] , was modified by repositioning of the pyridine nitrogen into the ortho and para positions and by desmethylation of the pyrrolidine nitrogen. A-84543, was originally synthesized by modification of the linker between the rings in nicotine [22] . This compound was chosen as lead because it fulfills the requirements of the pharmacophore model (see Fig. 1 ). Variation in the position of the nitrogen in the pyridine ring of A-84543, we reason, would alter the distance between the electronegative elements (N-N distance), and should yield a series of analogs that can be further characterized for their selectivity ratio and eventually their pharmacological footprint. From these analogs we may also be able to identify potential lead compounds suitable for development into drug candidates for the treatment of a neurological, mental, or autonomic diseases involving nAChRs. It should be clear, that such compounds could be full agonists, partial agonists or antagonists, depending on the condition. One also needs to keep in mind that highly efficacious agonists may have more severe adverse effects, and therefore low affinity or low efficacy compounds may have some advantages.
Materials
Unless otherwise noted, all chemicals were purchased from Sigma Aldrich (St. Louis, Mo). [ 3 H]EB was purchased from Perkin Elmer Life and Analytical Sciences (Boston, MA). Adult male rat whole brains were purchased from Pel-Freez Biologicals (Rogers, Arkansas).
Methods
For these studies we designed, synthesized and characterized a set of new nAChR ligands based on A-84543 where we changed the nitrogen in the pyridine ring from the meta position to the ortho and para positions, and further made more subtle structural changes by substituting the methyl group at the pyrrolidine nitrogen to a hydrogen atom. A-84543 and its analogs H-11MNH, H-11ONH, H-11ONM, and H-11PNH (Fig. 2) were prepared by reacting N-Boc-L-prolinol with the appropriate hydroxy pyridines (B, H, & I) using the method of Mitsunobu reaction as published by Mitsunobu et al. [43] and modified by Brown et al. [44] . M-xylene was used as the solvent and the reaction was conducted at room temperature. The progress of the Mitsunobu reaction and other synthetic steps were monitored by thin-layer chromatography (TLC) using precoated Merck silica gel Kiesegel 60 F 254 plates and spots were detected under UV light at 254 nm. After 72 h, excess 100 % ethylacetate was added and evaporated under reduced pressure. The resultant crude oil was dissolved on methanol and evaporated before purification via flash chromatography (3 % NH 4 OH; 5 % methanol; and 92 % ethylacetate) to yield the appropriate intermediate products E, F and G. Flash chromatography was conducted using silica gel 230-400 mesh. Separately, the intermediate products were dissolved in formic acid, mixed and 1.0 mmol of paraformaldehyde was added to each preparation. The mixture was stirred at 100°C for 3 h. When the intermediate products were completely consumed, as evidence by the disappearance of starting material on the TLC plate, the mixture was evaporated under reduced pressure and the resulting crude oily residue was stirred with 3 N HCl solution for 30 min. The aqueous solution was extracted with ethyl acetate (3 9 50 ml) to remove organic impurities and the remaining aqueous layer was basified with 6 N NaOH solution and then extracted several times with 100 % ethyl acetate. The ethyl acetate layer was concentrated to dryness to obtain A-84543 from E; and H-11ONM from F (see Fig. 2) .
To obtain H-11MNH, H-11ONH and H-11PNH, the intermediates E, F, and G were separately dissolved in ethyl acetate and drops of a solution of HBr in acetic acid were added to each solution until formation of a white precipitate (see Fig. 1 ). The mixtures were allowed to settle and the clear supernatant liquid was gently decanted to leave a whitish gel. To remove excess HBr, excess quantities of 100 % ethyl acetate were added, warmed, allowed to settle and the supernatant liquid was decanted. This step was repeated until a white insoluble solid was formed in the ethyl acetate. The solid was dried and stored in a desiccator. All compounds were characterized by Elemental analysis (C, H, and N ± 0.4 %). 1 H, 13 C and HETCOR NMR spectroscopy were recorded on a Bruker 400 MHz NMR instrument. The chemical shifts (d) were measured downfield in ppm relative to an internal standard of tetramethylsilane (TMS). Although H-11PNM was designed, it was not possible to synthesize it for this study.
Design and Determination of the Internitrogen Distance of the Analogs
Molecular modeling and comparative molecular field evaluation of the lead compound, A-84543 and five analogs were done using the SYBYL system (version 7.2) running on a Silicon Graphics Tezro (Department of Biochemistry and Molecular Biology, Howard University Washington, DC) to obtain the energy-minimized, conformational structure of the compounds. Energy minimization was performed on the compounds and on the bonds linking the two rings (pyridine and pyrrolidine rings). Because repositioning of the nitrogen in the pyridine ring and/or substitution on the nitrogen of the pyrrolidine ring would alter the distribution of electrons on the molecule, the Gasteiger-Huckel charge was estimated for each compound and the results are presented in Table 1 .
Binding Assays

Tissue Preparation
The tissue preparation and dissection of rat brain has been described elsewhere [20] . In brief, whole brains were obtained from adult male Sprague-Dawley rats (Pel-Freez Biologicals, Rogers AR). The brains were dissected and the cerebral cortices were removed and stripped of olfactory bulbs, hippocampus, caudate and septum. The brain was allowed to slightly thaw on a glass petri dish over ice, sliced and dissected to remove the cerebral cortex (CTX). Tissues were stored at -80°C until needed for binding assays. For all binding assays, the tissues were suspended and homogenized in ice cold 50 mM Tris-HCl buffer, pH 7.4 @ 4°C with a Brinkmann Polytron homogenizer. The homogenate was washed by centrifugation at 36,0009g for 20 min at 4°C. The supernatant was discarded and the resultant pellet was suspended in fresh buffer to give a final tissue concentration of 10 mg/100 lL, kept on ice, and vortexed again just before aliquoting it into the tubes.
Saturation Binding Assays
Saturation binding curves were used to determine the equilibrium dissociation constant and the B max values for 10 mg of tissue were obtained using a previously described method [19, 20] . Briefly, for saturation binding assays, 10 mg of CTX tissue were added to tubes containing 50 mM TrisHCl buffer pH 7.4 at ambient temperature and [ . Therefore, tubes containing CTX tissues, buffer and the radioligand were incubated for 4 h @ RT (*24°C). Non-specific binding was determined in parallel tubes incubated in the presence of 300 lM nicotine hydrogen tartrate (NIC) (Sigma Chemical Co. St. Louis, MO). In all assays, reactions were started by the addition of the CTX tissue homogenates. Specific binding was determined as the difference between total binding and non-specific binding. Incubations were terminated by vacuum filtration through Whatman GF/C filter papers, which were mounted on a Brandel cell harvester pre-wetted with 0.5 % polyethylenimine to reduce binding of free [ The filter papers were washed three times with 1.5 ml aliquots of 50 mM Tris-HCl buffer pH 7.4 @ RT. Radioactivity was measured in 500 ll of scintillation fluid using a beta liquid scintillation counter (1450 Microbeta Jet, Wallac Perkin Elmer, MD). The K D and B max values were determined by non-linear regression analysis using a computer assisted graph and statistical package (GraphPad prism 5 software Inc., San Diego, CA).
Competition Binding Assays in CTX
Competition assays were run with the synthesized compounds against 150 pM [ 3 H]EB to obtain the IC 50 and determine the affinity (K i ). Competition assays were done in parallel with well characterized nicotinic compounds for comparison. For all studies, nicotinic drugs and new synthesized compounds were diluted in buffer to obtain twelve serial dilutions ranging from *0.1 pM to 30 mM, depending on the compound (see Fig. 2 ). For each assay, the reaction was initiated by the addition of CTX tissue homogenate (10 mg) to give a final assay volume of 1.0 ml. Nonspecific binding was determined in parallel preparations incubated with 300 lM nicotine hydrogen tartrate. Specific drug binding was defined as the difference between total binding and binding in the presence of drug minus nonspecific binding. Incubation time was 4h @ RT and was terminated by vacuum filtration through Whatman GF/C filter papers as described above [19] . The filter papers were washed three times with 1 ml aliquots of 50 mM Tris-HCl buffer and the radioactivity bound to the filter papers was measured in a liquid scintillation counter (1450 Microbeta Jet, Wallac Perkin Elmer, MD). The IC 50 values for each experiment were determined by non-linear regression analysis (GraphPad Prism 5 software Inc., San Diego, CA). The K i s in CTX tissue for all compounds were calculated using the Cheng-Prusoff equation [45] where the K D was 35 nM, as per the saturation curve.
Competition Binding Assays in Transfected Cell Lines
To determine the selectivity of the ligands for different nAChR subtypes, competition binding was done using 
Results
N-N Distance
The distance between the two nitrogen atoms (N-N distance) from A-84543, and all designed A-84543 analogs were calculated to be between 6.4 and 8.2 Å . An intermediate distance of *7 Å was found in A-84543 and H-11MNH (3-pyridyl ether compounds) earlier [22] . H-11MNH differs from A-84543 by a substitution of the methyl group at the pyrrolidine nitrogen to a hydrogen atom, a proton (see Table 1 ). As a result of this small structural difference, the Gasteiger-Huckel charges for A-84543 and H-11MNH were -360 and -371 eV at the pyrrolidine nitrogens respectively; indicating a small difference of 11 eV in the distribution of electrons at this nitrogen atom. These 3-pyridyl ethers showed the highest affinity at nAChRs [32] . The distribution pattern of electrons on the pyrrolidine nitrogen was maintained in the 2-pyridyl ether analogs (H-11ONH and H-11ONM) and 4-pyridyl ether analogs (H-11PNH and H-11PNM). However, the electron distribution on the pyridine nitrogen was different for each group of analogs. The Gasteiger-Huckel charge on the pyridine nitrogen for the 2-pyridyl ethers was found to be -274, and -313 eV for the 4-pyridyl ether compounds compared to -307 eV on the pyridine ring of the 3-pyridyl ether compounds.
Saturation Curves
Under the present conditions specific binding of [ 3 H]EB in the CTX tissue homogenates was saturable (Fig. 3) . The dissociation constant (K D ) for rat brain cortex was found to be 35 pM with a B max of 45.9 fmol/mg tissue (Fig. 3) .
Binding in CTX
Competition binding assays were used to determine the affinity (Ki) of the compounds using 150 pM [ 3 H]EB. A concentration of 150 pM was chosen to be above the experimentally determined K D for high affinity CTX receptors (K D * 25-100 pM) and close to the K D for lower affinity CTX receptors (K D * 100-500 pM) [23, 24] . Thus, at this concentration most high affinity sites and at least 15-30 % of the low affinity sites would be labeled. All synthesized compounds were found to be competitive ligands at nAChRs despite the different position of their nitrogen atom in the pyridine ring, or whether they had a methyl or a hydrogen in the pyrrolidine nitrogen, however, they had hugely different affinities (Fig. 4) . Nicotine, the standard drug at nAChRs, DHBE, a relatively selective b2-antagonist, and A-85380, another well characterized nicotine-derived analog previously described by Sullivan et al. [23] , were used for comparison (Fig. 4) . Thus, the affinity of H-11MNH was found to be highest for CTX nAChRs, and about the same as that of A-85380 (Ki values of 0.46 ± 0.21 nM vs 0.37 ± 0.11 nM, respectively) but tenfold greater than the affinity of the lead compound A-84543 (Ki = 3.44 ± 0.79 nM). In general, the affinity of the compounds was greater in those compounds containing the proton attached to the pyrrolidine nitrogen compared to the compounds with a methyl group in the same position. Since compound H-11PNM was not easily synthesized, it was not characterized further.
Binding in Cell Lines
Under the established conditions, H-11MNH was by far the competitive analog with highest affinity for most nAChRs examined followed by A-84543. All other compounds, although competitive for the nAChRs, were of extremely low affinity ([10,000 nM) (see Table 3 ). Binding of A-84543 (diamond), H-11ONM (asterisk), H-11MNH (circle), H-11ONH (plus symbol) and H-11PNH (multiplication symbol), were compared to that of A-85380 (filled square), a high affinity nAChR agonist, DHbE (triangle) a high affinity nAChR antagonist, and Nicotine (inverted triangle). The data were analyzed by nonlinear least square regression method using GraphPad Prism 5 software (GraphPad Software Inc. San Diego, CA). IC 50 and K i values are presented in Table 2 . The data shown is representative of n = 3-6 independent experiments for each compound run in triplicates Binding of A-84543, its analogs, and A-85380 was compared to that of nicotine and the nicotinic b2 receptor antagonist DHbE in rat CTX tissue homogenates (10 mg) in a total volume of 1 ml for 4 h @ RT (*24°C). The inhibition constants (K i ) were calculated using the For comparison purposes, the affinities of the drugs were examined in parallel with membrane homogenates of adult male whole forebrain (FB). Whole FB tissue is thought to contain predominantly the a4b2 nAChR subtype [17] and has been previously used for comparison purposes [19, 24, 25] . A-84543 and H-11MNH showed a similar order of binding affinities in both adult rat FB compared to cultured transfected cells. Both compounds were better at competing for the a4b2 than for the a3b4 nAChR binding site. Although it should also be noted that the affinities of A-84543 and H-11MNH are at least 2 times higher or more at a4b2 nAChRs expressed in transfected cells than at a4b2 nAChRs from rat FB homogenates. As with CTX tissue homogenate, all other analogs had very low affinity for the a4b2 FB nAChRs (Table 3) .
In order to assess the selectivity of the compounds between nAChR subtypes; the selectivity ratio was calculated using the binding affinity constants (K i ). The values are shown in Table 4 . In transfected cell lines, the lead compound A-84543 was found to be 1357 times more selective for a4b2 nAChRs than for the a3b4 subtype. In contrast, H-11MNH was *530 times more selective for a4b2 than for the a3b4 nAChR subtypes. On the other hand nicotine only showed a 50 fold selectivity between these receptors. Interestingly, when the selectivity ratio for a3b4 was compared with a2b4 using adult rat FB tissue, the selectivity ratio for both A-84543 and H-11MNH were similar at *300. Comparing the affinity of the drugs between a7 and a4b2 also shows H-11MNH to have a high affinity ratio of 622 towards a4b2, although, it falls short of Binding was done against *500 pM [ Data indicate that A-84543 has the greatest selectivity ratio for a4b2 compared to a3b4 nAChR expressed in transfected cell lines (Only I-A-85380 (not shown) has a higher selectivity ratio of *4000 [24] ). H-11MNH showed moderate selectivity ratios between a3b4 compared to a4b2 or a4b2*FB, on the other hand it has the highest affinity for a7 compared to A-84543 or A-85380 yet still a good ratio between a7 and a4b2. Interestingly, A-84543 and H-11MNH, as well as nicotine and A-85380, have low selectivity ratios between a3b4 and a7 nAChRs with great implications for the interpretation of their pharmacological and physiological functions a The selectivity ratios were determined from the K i of the compounds in a4b2, a3b4, and a7 stably transfected cells b Selectivity ratio was determined using rat forebrain (FB) as the natural a4b2 receptor vs receptor expressed in stably transfected cells c Values for A-85380 have been added only for the purpose of comparison from Ref [24] A-85380's affinity ratio of *3000 between these two subtypes. Finally, the affinity ratio for most drugs between a3b4 and a7 is poor (\ than 6), thus one needs to be cautious on using adequate pharmacological tools to differentiate between these two subtypes. 
Rb
? efflux in neuroblastoma IMR-32 cells, and A-84543, H-11MNH and analog 3b were also found to be full agonists, while analog 2b was an antagonist. IMR-32 cells are thought to possess predominantly ganglionic-like a3b4 nAChR subtypes, however, they express a3, a5, a7, b2, and b4 AChR subunits and thus potentially several other nAChRs. Therefore, A-84543 and H-11MNH were further tested here for their function at a3b4 nAChRs expressed in HEK 293 cells. In this assay, the a3b4 transfected cells were loaded with 86 Rb
? and then stimulated with various concentrations (0.1 nM-10 mM) of either A-84543, H-11MNH, or nicotine to allow for 86 Rb ? efflux to occur. During this assay, a separate group of cells was treated with 100 lM nicotine to establish the E max . Nicotine's EC 50 was determined to be *32 lM with maximal efficacy. Efficacy for H-11MNH was found to be 83.33 % with an EC 50 of 24 ± 1 lM, thus it is a full agonist with moderate potency at these nAChRs. In contrast, A-84543 was determined to be a partial agonist (37.5 % of E max ) with an EC 50 of 160 ± 4 lM, a potency sixfold lower than that of H-11MNH (Table 5) .
Discussion
Clinical and preclinical data suggests that nAChRs are involved in many neurophysiological functions in both the central and peripheral nervous systems, as well as many nonneuronal tissues [13] , including immune cells [47] . The diversity of native nAChRs and their selective involvement in so many physiological functions and potential neuropathologies makes them great candidates as clinical therapeutic targets. Encouraged by the high affinity of 3-pyridyl analogs, many researchers have attempted to improve the selectivity of this class of compounds for specific nAChR subtypes. In line with this reasoning, Wei et al. [48] demonstrated the importance of attachment of a hydrophobic or hydrogen bonding alkynyl group to the C5 position of the pyridyl ring of EB and A-84543 in order to improve selectivity for neuronal nAChR subtypes. It was therefore postulated here that attachment of electron withdrawing or electron donating substituents to the ortho and para positions would generate A-84543 analogs that differ in their affinity for nAChRs. Therefore, several analogs of A-84543 were synthesized that vary in the distance between their nitrogens, to test if this would confer greater binding ability or selectivity for the orthosteric site in the nAChRs. Differential positioning of the nitrogen and exchanging the methyl group for a hydrogen in the lead molecule changed the selectivity of the analogs for nAChRs. The charge on the pyridine or pyrrolidine nitrogens was not very different between the compounds. However, the N-N distance for both A-84543 and H-11MNH was found to be intermediate (*7 Å ) between that for the other two pairs of compounds (*6 or 8 Å ), and this may be important in conferring these ligands their high affinity (in the nanomolar range for A-84543 and picomolar range for H11MNH) for nAChRs, versus 10,000 for other analogs (H-11ONH and H-11ONM, or H-11PNH). Although this goes against the three models proposed by Abreo et al., [22] .
After synthesizing A-84543 and its analogs, competition assays were performed to determine if they would bind at the nAChRs. All the analogs were found to be competitive, although, as stated before, with very diverse affinities. H-11MNH had the highest affinity (*0.5 nM) for CTX nAChRs, while H-11ONM had the lowest (*60,000 nM). The rank order for the analogs at displacing 150 pM
The compounds were then tested for selectivity in stably transfected HEK cells expressing different nAChRs subtypes, here again, A-84543 and its analog H-11MNH, showed high affinity for most nAChRs. Of all the analogues, H-11MNH showed highest affinity for all nAChRs while A-84543 had a *5 to 10-fold lower affinity. All other compounds had very low affinities ([10,000 nM). Interestingly, other than having high affinity, A-84543 and H-11MNH had very distinct pharmacological profiles, and both differ from that of nicotine and A-85380. Both A-84543 and H-11MNH had highest affinity for a2b2 and a4b2 nAChRs and showed moderate affinity for b4-and a7-containing receptors, which makes them interesting for further functional characterization. Interestingly, A-84543 had the greatest selectivity ratio for a4b2 vs a3b4 nAChR but moderate ratio between a4b2 from FB and a3b4. This also calls for further studies to determine what element in the receptor's binding site determines this large difference in binding affinity. The differences may be due to the presence of small variations in assembly between the subunits, or perhaps a different stoichiometry of the subunits assembled. One must always take into account that the machinery between the human embryonic kidney cells, HEK cells, and the neurons in rat FB or CTX may be different and potentially affect the final form of the receptor. For example a slight change in the glycosylation of the receptor may be enough to cause a small change in drug affinity. The moderate affinity ratio between a4b2 and a7, also requires further investigation especially of drugs thought to be exclusively b2-selective (non-classical a7 nicotinic drugs) on a7 nAChRs, or drugs a7-selective (non-classical b2 nicotinic drugs) on b2-containing nAChRs to determine if indeed they are without functional effects on the other nAChRs. H-11MNH only has moderate selectivity ratios between a4b2 vs a3b4, and a4b2 vs a7 nAChRs, thus, this observation may be important for further investigation to understand the properties of the orthosteric site, since the natural ACh molecule also has moderate selectivity ratios between many nAChRs [24, 25, 28] . Both A-84543 and H-11MNH have a very low selectivity ratio between a3b4 and a7 nAChRs and this should also be further warning that compounds are not as clean as we would like to assume, and that they can interact with multiple nAChRs and sometimes even with unexpected receptor subtypes, and that they may act differentially as full agonists in some nAChR subtypes, partial agonists in others, or antagonists in yet other subtypes. For example, previously published data [22] showed that conformers of A-84543 (2a and 2b), and those for H-11MNH (3a and 3b) bind [ 3 H]-cytisine-sensitive sites (a4b2 and a3b4*) with high affinity. Back then it was thought that [ 3 H]cytisine was a selective b2-containing receptor ligand. However, we now know it is a partial agonist at a4b2 nAChRs (with high potency) and a full agonist at a3b4 nAChRs (with low potency). It is important to also mention that other drugs, such as veranicline, have also been found to be full agonists at a3b4 receptors, although they seem to have low potency for them as well, and are partial agonists at a4b2-containing nAChRs (with high potency) [49] . A-84543 and H-11MNH, nevertheless, were found to both be full agonists at a4b2 human receptors expressed in K177 cells and in ganglioniclike a3b4* nAChRs naturally found in the neuroblastoma derived IMR-32 cells using 86 Rb efflux assays [22] . Although IMR-32 cells have more than one nAChR subtype [50] . Noteworthy is Abreo's study [22] , where A-84543 (2a) and its conformer 2b were quite different in their potency and efficacy at nAChRs in K177 cells, but had similar affinity at those in IMR-32 cells, albeit hugely different efficacies. While H-11MNH (3a) and its conformer 3b had similar potency and efficacy at nAChRs in K177, as well as in IMR-32 cells.
Altogether, we have not shown a direct correlation between affinity and nitrogen distance, although an intermediate distance of 7 Å seems desirable for these analogs, it is not necessary, nor was there a correlation with the Gasteiger-Huckel charge in the pyridyl nitrogen or pyrrolidine nitrogen. Nevertheless, repositioning of the pyridyl nitrogen does not alter the competitive nature of the pyridyl ethers but does result in changes in the affinities of the ligands for the nAChR subtypes. Out of five analogs only A-84543 and H-11MNH have high affinity for the CTX a4b2 nAChRs, as proposed previously against [ 3 H]cytisine [22] . Here we also demonstrate they have reasonable affinity for a3b4 and a7 nAChRs. In contrast, the 2-and 4-pyridyl ether analogs have negligible affinity. We also demonstrated that H-11MNH has higher potency and higher efficacy compared to A-84543 at a3b4 nAChRs. It is possible that further modifications of A-84543 or H-11MNH may still hold potential for enhanced affinity, potency and efficacy at select nAChRs.
Continued development and detailed characterization of new ligands with different nAChR subtype profiles may ultimately allow for the design of more subtype-specific compounds that may shed light on the biophysical story of how these receptors ultimately function. It is important to note that positive and negative allosteric modulators also have a role to play and should make important contributions, in conjunction with orthosteric ligands, in the functional characterization of nAChR subtypes since their selectivity does not dependent on the orthosteric binding site [51] [52] [53] [54] . This should allow for some interesting and innovative modulation of the nAChRs.
